BerandaARCT • NASDAQ
add
Arcturus Therapeutics Holdings Inc
$12,91
Setelah Jam Perdagangan Normal:(0,23%)-0,030
$12,88
Tutup: 25 Apr, 20.00.00 GMT-4 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$12,89
Rentang hari
$12,29 - $12,98
Rentang tahun
$8,04 - $44,99
Kapitalisasi pasar
350,12Â jt USD
Volume Rata-Rata
428,97Â rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 22,77Â jt | -26,22% |
Biaya operasional | 12,38Â jt | -1,02% |
Laba bersih | -30,00Â jt | -156,30% |
Margin laba bersih | -131,80 | -247,39% |
Penghasilan per saham | -1,11 | -246,88% |
EBITDA | -32,58Â jt | -86,60% |
Tarif pajak efektif | 0,01% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 237,03Â jt | -18,83% |
Total aset | 344,07Â jt | -19,87% |
Total liabilitas | 103,09Â jt | -31,68% |
Total ekuitas | 240,98 jt | — |
Saham yang beredar | 27,12 jt | — |
Harga terhadap nilai buku | 1,45 | — |
Tingkat pengembalian aset | -23,36% | — |
Tingkat pengembalian modal | -29,77% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -30,00Â jt | -156,30% |
Kas dari operasi | -284,00Â rb | 54,85% |
Kas dari investasi | 0,00 | 100,00% |
Kas dari pembiayaan | 134,00Â rb | 100,72% |
Perubahan kas bersih | -150,00Â rb | 99,26% |
Arus kas bebas | 9,53Â jt | 143,91% |
Tentang
Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA.
The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. As of 2021, vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. Wikipedia
Didirikan
2013
Situs
Karyawan
175
